PIPERAZINE CITRATE


Trade Names	ANTEPAR BRYREL MULTIFUGE PIPERAZINE CITRATE VERMIDOL
Synonyms	Antepar Bryrel Multifuge Piperazine citrate Vermidol
Status
Molecule Category	Salt-form
UNII	63KP7FXF2I


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JDDHUROHDHPVIO-UHFFFAOYSA-N
Smiles	C1CNCCN1.C1CNCCN1.C1CNCCN1.O=C(O)CC(O)(CC(=O)O)C(=O)O.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI	InChI=1S/2C6H8O7.3C4H10N2/c27-3(8)1-6(13,5(11)12)2-4(9)10;31-2-6-4-3-5-1/h213H,1-2H2,(H,7,8)(H,9,10)(H,11,12);35-6H,1-4H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H48N6O15
Molecular Weight	660.67
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Bioactivity

Mechanism of Action	Action	Reference
Nematode GABA-A receptor positive modulator	POSITIVE MODULATOR	ISBN PubMed PubMed Wikipedia Wikipedia

Cross References

Resources	Reference
ChEMBL	CHEMBL3989678
FDA SRS	63KP7FXF2I
PubChem	131801040
ChEBI	79399
ChEMBL	CHEMBL3990694
FDA SRS	RI85381D5G
KEGG	C13660
PubChem	131801040
SureChEMBL	SCHEMBL94288

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).